UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063661
Receipt number R000072835
Scientific Title Long-Term Changes in Corneal Endothelial Cell Density Following Endoscope-Guided PreserFlo MicroShunt Implantation in the Ciliary Sulcus in Eyes with Glaucoma: A Prospective Observational Study Including an Exploratory Comparison With Anterior Chamber Implantation
Date of disclosure of the study information 2026/11/17
Last modified on 2026/11/17 09:58:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Five-Year Observational Study of Corneal Endothelial Cell Changes After PreserFlo MicroShunt Implantation in the Ciliary Sulcus in Patients With Glaucoma

Acronym

PreserFlo Sulcus Study

Scientific Title

Long-Term Changes in Corneal Endothelial Cell Density Following Endoscope-Guided PreserFlo MicroShunt Implantation in the Ciliary Sulcus in Eyes with Glaucoma: A Prospective Observational Study Including an Exploratory Comparison With Anterior Chamber Implantation

Scientific Title:Acronym

Sulcus-PFM ECD Study

Region

Japan


Condition

Condition

Glaucoma

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The primary objective of this prospective observational study is to evaluate long-term changes in corneal endothelial cell density (ECD) from baseline to 60 months after endoscope-guided PreserFlo MicroShunt implantation in the ciliary sulcus in eyes with glaucoma. ECD will be assessed in nine corneal regions, including the central region and eight peripheral regions, to determine the absolute change and percentage reduction at 60 months. As a secondary exploratory objective, longitudinal changes in ECD will be compared with those in eyes undergoing conventional anterior chamber implantation.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Percentage reduction and absolute change from baseline to 60 months in the equally weighted mean corneal endothelial cell density (ECD) across nine corneal regions (the central region and eight peripheral regions) following PreserFlo MicroShunt implantation in the ciliary sulcus.

Eyes with technically successful ciliary sulcus implantation will be analyzed. ECD measurements obtained at baseline and 3, 6, 12, 18, 24, 36, 48, and 60 months postoperatively will be analyzed using a linear mixed-effects model. The primary estimate will be the percentage reduction in ECD at 60 months.

Key secondary outcomes

1. ECD: Absolute and percentage changes in each of nine corneal regions from baseline to 60 months; regional differences; annual changes in the equally weighted nine-region mean ECD from 6 to 60 months; and comparison of primary sulcus implantation with sulcus reimplantation.

2. Exploratory comparison with anterior chamber implantation: Nine-region mean ECD trajectories, absolute and percentage changes at 60 months, regional ECD changes, and corneal events. Only primary implantations will be compared, using overlap weighting to adjust for baseline characteristics.

3. Low baseline ECD: Associations between baseline ECD and postoperative ECD changes; ECD trajectories in eyes with baseline ECD of 1000 cells/mm2 or less; incidence and timing of corneal edema, endothelial decompensation, corneal transplantation, central ECD below 500 cells/mm2, and unmeasurable ECD due to corneal damage through 60 months.

4. IOP and glaucoma treatment: IOP, IOP reduction, and medication counts at baseline and 1, 3, 6, 12, 18, 24, 36, 48, and 60 months; additional glaucoma surgery and its timing.

5. Visual function and OCT: Visual acuity through 60 months; visual field mean deviation at baseline and 12, 24, 36, 48, and 60 months; macular GCC and peripapillary RNFL thickness at baseline and 3, 6, 12, 18, 24, 36, 48, and 60 months; and macular OCT morphology.

6. Anterior segment OCT: Tube position at 1 month, bleb morphology at 3 months, and their associations with IOP reduction.

7. Surgical feasibility and safety: Technical success and conversion rates among all attempted sulcus implantations; associations of surgical techniques with success and complications; intraoperative and postoperative complications, additional procedures, glaucoma surgery, tube removal, and corneal events through 60 months.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who meet all of the following criteria will be eligible:

1. Patients diagnosed with glaucoma at Toyama University Hospital who are scheduled to undergo PreserFlo MicroShunt implantation in the ciliary sulcus or anterior chamber as part of routine clinical care.
2. Patients aged 18 years or older at the time of surgery.
3. Patients undergoing the eligible surgery during the study period after ethics committee approval.
4. Patients with at least one valid preoperative corneal endothelial cell density (ECD) measurement among nine corneal regions, including the central region and eight peripheral regions.
5. Patients who provide written informed consent for study participation before surgery.

The sulcus group will include both primary implantation and sulcus reimplantation following previous anterior chamber implantation. The anterior chamber group will generally include primary implantation cases. Combined cataract surgery will be permitted. If both eyes are eligible, only the first eye undergoing the eligible surgery during the study period will be included in the analysis.

Key exclusion criteria

Patients meeting any of the following criteria will be excluded:

1. Patients in whom preoperative corneal endothelial cell density (ECD) cannot be measured in any of the nine corneal regions, including the central region and eight peripheral regions.
2. Patients who do not provide written informed consent for participation in the study.
3. Patients considered unsuitable for participation by the principal investigator or other study investigators for medical or study-related reasons.

Target sample size

480


Research contact person

Name of lead principal investigator

1st name Atsushi
Middle name
Last name Hayashi

Organization

Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama

Division name

Department of Ophthalmology

Zip code

930-0194

Address

2630 Sugitani, Toyama City

TEL

0764347367

Email

ahayashi@med.u-toyama.ac.jp


Public contact

Name of contact person

1st name Mitsuya
Middle name
Last name Otsuka

Organization

Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama

Division name

Department of Ophthalmology

Zip code

930-0194

Address

2630 Sugitani, Toyama City

TEL

0764347363

Homepage URL


Email

otsuka@med.u-toyama.ac.jp


Sponsor or person

Institute

University of toyama

Institute

Department

Personal name



Funding Source

Organization

University of Toyama

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research Ethics Committee for Clinical and Epidemiological Research of Toyama University

Address

2630 Sugitani, Toyama City

Tel

0764158857

Email

rinri@adm.u-toyama.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 10 Month 10 Day

Date of IRB

2026 Year 11 Month 13 Day

Anticipated trial start date

2026 Year 12 Month 01 Day

Last follow-up date

2036 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This is a single-center, two-cohort, prospective observational study conducted at Toyama University Hospital. Patients with glaucoma undergoing PreserFlo MicroShunt implantation in the ciliary sulcus or anterior chamber as part of routine clinical care will be enrolled. Surgical indications and tube placement locations will be determined by the treating surgeons independently of study participation. No study-related allocation, additional examinations, or therapeutic interventions will be performed.

The target sample size is 480 patients (480 eyes), comprising 240 patients with technically successful ciliary sulcus implantation and 240 patients undergoing anterior chamber implantation. Patients will be followed for up to 60 months after surgery. Cases in which sulcus implantation is attempted but converted to anterior chamber implantation or another procedure will be recorded separately for the assessment of technical success and safety, without being counted toward either target cohort.

The sulcus group will include primary implantation and sulcus reimplantation following removal of a previously implanted anterior chamber device. Exploratory comparisons with the anterior chamber group will be restricted to primary implantation cases, with adjustment for baseline characteristics using overlap weighting.

Ciliary sulcus implantation of the PreserFlo MicroShunt is an off-label procedure, and separate informed consent for the surgery will be obtained independently of research participation consent. An exploratory interim analysis of outcomes through 12 months is planned, while the final analysis of the primary outcome will use data through 60 months.


Management information

Registered date

2026 Year 11 Month 17 Day

Last modified on

2026 Year 11 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072835